首页> 美国卫生研究院文献>High-Throughput >Retrospective Proteomic Analysis of Cellular Immune Responses and Protective Correlates of p24 Vaccination in an HIV Elite Controller Using Antibody Arrays
【2h】

Retrospective Proteomic Analysis of Cellular Immune Responses and Protective Correlates of p24 Vaccination in an HIV Elite Controller Using Antibody Arrays

机译:艾滋病毒精英控制器中使用抗体阵列的细胞免疫反应和p24疫苗的保护性相关性的回顾性蛋白质组学分析。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background: HIV p24 is an extracellular HIV antigen involved in viral replication. Falling p24 antibody responses are associated with clinical disease progression and their preservation with non-progressive disease. Stimulation of p24 antibody production by immunization to delay progression was the basis of discontinued p24 vaccine. We studied a therapy-naive HIV+ man from Sydney, Australia, infected in 1988. He received the HIV-p24-virus like particle (VLP) vaccine in 1993, and continues to show vigorous p24 antigen responses (>4% p24-specific CD4+ T cells), coupled with undetectable plasma viremia. We defined immune-protective correlates of p24 vaccination at the proteomic level through parallel retrospective analysis of cellular immune responses to p24 antigen in CD4+ and CD8+ T cells and CD14+ monocytes at viremic and aviremic phases using antibody-array. We found statistically significant coordinated up-regulation by all three cell-types with high fold-changes in fractalkine, ITAC, IGFBP-2, and MIP-1α in the aviremic phase. TECK and TRAIL-R4 were down-regulated in the viremic phase and up-regulated in the aviremic phase. The up-regulation of fractalkine in all three cell-types coincided with protective effect, whereas the dysfunction in anti-apoptotic chemokines with the loss of immune function. This study highlights the fact that induction of HIV-1-specific helper cells together with coordinated cellular immune response (p < 0.001) might be important in immunotherapeutic interventions and HIV vaccine development.
机译:背景:HIV p24是一种参与病毒复制的细胞外HIV抗原。下降的p24抗体反应与临床疾病进展及其与非进行性疾病的保存相关。通过免疫刺激p24抗体生产以延缓病情是终止p24疫苗的基础。我们研究了一位来自澳大利亚悉尼的未治疗过的HIV +男性,该男性于1988年感染。他于1993年接受了HIV-p24-病毒样颗粒(VLP)疫苗,并继续表现出强烈的p24抗原应答(> 4%p24特异性CD4 + T细胞),加上无法检测到的血浆病毒血症。通过平行回顾性分析CD4 + 和CD8 + T细胞和CD14 单核细胞。我们发现,在非生物素体阶段,所有三种细胞类型在分数链烷烃,ITAC,IGFBP-2和MIP-1α中具有高倍变化的统计上显着的协同上调。 TECK和TRAIL-R4在病毒血症阶段下调,在非病毒血症阶段上调。在所有三种细胞类型中,fractalkine的上调都与保护作用相吻合,而抗凋亡趋化因子的功能障碍则伴随着免疫功能的丧失。这项研究强调了一个事实,即HIV-1特异性辅助细胞的诱导以及协同的细胞免疫应答(p <0.001)可能在免疫治疗干预和HIV疫苗开发中很重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号